Lusutrombopag

Lusutrombopag, sold under the brand name Mulpleta among others, is a medication that has been developed for certain conditions that lead to thrombocytopenia (abnormally low platelet counts) such as thrombocytopenia associated with chronic liver disease in patients prior to elective invasive procedures.^[1] It is being manufactured in Philadelphia, PA and marketed in Japan by Shionogi.^[2][3][4] It was approved by the U.S. Food and Drug Administration (FDA) in July 2018, and NICE in January 2020.^[5][6]

Lusutrombopag

Clinical data
Pronunciation	loo" soo trom' boe pag
Trade names	Mulpleta, Mulpleo
AHFS/Drugs.com	Monograph
MedlinePlus	a618043
License data	EU EMA: by INN US DailyMed: Lusutrombopag
Routes of administration	By mouth
ATC code	B02BX07 (WHO)
Legal status
Legal status	US: ℞-only EU: Rx-only In general: ℞ (Prescription only)
Identifiers
IUPAC name (E)-3-[2,6-Dichloro-4-[[4-[3-[(1S)-1-hexoxyethyl]-2-methoxyphenyl]-1,3-thiazol-2-yl]carbamoyl]phenyl]-2-methylprop-2-enoic acid
CAS Number	1110766-97-6 Y
PubChem CID	49843517
DrugBank	DB13125 Y
ChemSpider	21106301 Y
UNII	6LL5JFU42F
KEGG	D10476
ChEMBL	ChEMBL461101 N
CompTox Dashboard (EPA)	DTXSID701027951
Chemical and physical data
Formula	C29H32Cl2N2O5S
Molar mass	591.54 g·mol−1
3D model (JSmol)	Interactive image
SMILES CCCCCCO[C@@H](C)c1cccc(-c2csc(NC(=O)c3cc(Cl)c(/C=C(\C)C(=O)O)c(Cl)c3)n2)c1OC
InChI InChI=1S/C29H32Cl2N2O5S/c1-5-6-7-8-12-38-18(3)20-10-9-11-21(26(20)37-4)25-16-39-29(32-25)33-27(34)19-14-23(30)22(24(31)15-19)13-17(2)28(35)36/h9-11,13-16,18H,5-8,12H2,1-4H3,(H,35,36)(H,32,33,34)/b17-13+/t18-/m0/s1 Y Key:NOZIJMHMKORZBA-KJCUYJGMSA-N Y
NY (what is this?)

It was approved for medical use in the European Union in February 2019.^[7]